Saladax Biomedical actively pursues strategic alliances for co-promotion and/or distribution of its proprietary line of MyCare™ products. We seek leaders in the in-vitro diagnostic industry that market instrument platforms on which MyCare tests will be performed, major reference laboratories that would offer MyCare testing services, and pharmaceutical companies that market anticancer drugs that would further enhance patient outcomes via the Saladax MyCare technology platform.
April 2010
Saladax Biomedical, Inc. executed an exclusive distribution agreement with FALCO SD HOLDINGS Co., Ltd. of Kyoto, Japan (www.web.falco.co.jp/english) for the Saladax My5-FU test kit in the Japanese market. (Read More)
May 2009
Saladax entered into a non-exclusive distribution agreement with Lab21 of Cambridge, UK for the Company’s My5-FU assay in the UK and markets in the Middle East. (Read More)
October 2008
Saladax finalized an agreement with Roche Diagnostics (SWISS: RO.SW, www.roche.com) for the distribution of the Roche cobas c 111 analyzer which serves as a delivery platform for all Saladax MyCare assays currently under development.
September 2008
Saladax announced the finalization of an exclusive North American licensing agreement with Myriad Genetics (Nasdaq: MYGN, www.myriad.com) for the My5-FU technology, enabling Myriad to offer 5-FU dose management testing services under the trade name OnDose™. (Read More). Myriad subsequently launched the My5-FU Assay under the trade name OnDose™. (Read More).
“Our ability to attract industry leaders as collaborators attests to the continued success of Saladax Biomedical. With a robust pipeline of proprietary products, we will continue to actively seek partnerships to assure the long-term success of our portfolio.”
Partnering contact:
Adrienne Choma, Esq.
President and COO
Saladax Biomedical, Inc.
116 Research Drive
Bethlehem, PA 18015
E-mail: achoma@saladax.com
Phone: (201) 240-4072
Fax: (610) 849-5001